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Myocardial infarctionMore than4.2 billion inhabitants populate theAsia-Paciﬁc region. Acute coronary syndrome (ACS) is now amajor
cause of death and disability in this region with in-hospital mortality typically exceeding 5%. Yet, the region still
lacks consensus on the best approach to overcoming its speciﬁc challenges in reducing mortality from ACS.
The Asia-Paciﬁc Real world evIdenCe on Outcome and Treatment of ACS (APRICOT) project reviewed current
published and unpublished registry data, unmet needs inACSmanagement and possible approaches towards im-
proving ACS-related mortality in the region. There was striking heterogeneity in the use of invasive procedures,
pharmacologic practice (hospitalization/post-discharge), and in short- and long-term clinical outcomes across
healthcare systems; this heterogeneity was perceived to be far greater than in Western Europe or the United
States. ‘Benchmark’ short-term clinical outcomes are preferred over long-term outcomes due to difﬁculties in
follow-up, recording and maintenance of medication adherence in a geographically large and culturally diverse
region. Key ‘barriers’ towards improving outcomes include patient education (pain awareness, consequences
of missing medication and secondary prevention), geographical landscape (urban vs. metropolitan), limited
long-term adherence to guideline-based management and widespread adoption of cost-based rather than
value-based healthcare systems. Initiatives to overcome these barriers should include implementation of pre-
hospital management strategies, toolkits to aid in-hospital treatment, greater community outreach with online
patient/physician education and telemedicine, sustainable economic models to improve accessibility to effective
pharmacotherapies and the acquisition of high-quality ‘real-world’ regional data to tailor secondary prevention
initiatives that meet the unique needs of countries in this region.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease (CVD) is the leading cause of death world-
wide, accounting for 17.3 million deaths in 2008 (or ~30% of all deathsedicine, Yong Loo Lin School of
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land Ltd. This is an open access articlworldwide). Coronary artery disease and acute coronary syndrome
(ACS) together account for approximately 7 million deaths each year
[1,2]. The Asia-Paciﬁc region comprises ~50 countries, including seven
from 10 of themost densely populated countries worldwide. The region
is populated by more than 4.2 billion inhabitants, equivalent to ~60% of
theworld's population, with a combined gross domestic product of ~US
$18 trillion growing at ~6% per annum [3,4]. ACS is now a leading cause
of mortality in the Asia-Paciﬁc region, accounting for around half of the
global burden [2]. In fact, due to rapid industrialization, fewer than 50%
of patients across the Asia-Paciﬁc region attain the National Cholesterol
Education Program Adult Treatment Panel lII low-density lipoprotein
cholesterol target [5,6].
Guidelines for themanagement of ACS in Australia and New Zealand
are generally comparable with those from Europe and the USA [7–13]
while guidelines across other parts of Asia show variability accordinge under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 (continued)
Mortality (%)
(invasive treatment)
Mortality (%)
(non-invasive treatment)
Country/
registry STEMI (%)
B. Invasive versus non-invasive intervention
IH 12-month IH 12-month
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improved adoption of evidence-based recommendations over the last
decade strongly correlates with reduction in both in-hospital and
post-discharge ACS-related mortality (up to 25%) [17,18]. These
improvements have largely been attributed to timely and effective
reperfusion, as well as standardized pharmacological approaches
[17]. In contrast, registry-based data from the Asia-Paciﬁc regionTable 1
Mortality data across Asian-Paciﬁc countries according to (A) disease status and (B) invasive
versus non-invasive intervention [21–37,40,43,45,47–50,52,54,61–64,68–70].
Overall
A. Disease status
Mortality (%) MACE (%)
Country/
registry STEMI (%) IH 12-month PCI (%) IH 12-month
Australia/
New 
Zealand
~35 2−4 5−10 100 − 14−16
42 − 10 14−71 − −
~10* 4.5 − 43 5-29 −
China ~44 1−7 − 49 − −
43 5 − 38† − −
63 ≥19 − <25 − −
0 − 8d 23 − −
99 − − 12 10 −
100 − 12−25 20−31 − −
16 1 3 65 2 9
0 1 − 44 3 −
India 61 − 7a 8 − −
37 4 − 12 6 −
Japan 79 9 − 74 40 −
100 3 − 97 − −
− 6 9 100 7−11 14−21 e
59 2 4 94 − 6d
Korea 60 4−6 11−14 − − 20−23
100 − 7−13 96−97 − 10−17
Malaysia 47 4−10 − 13−17 − −
52 1 − 100 − −
Singapore − − 25b − − −
30 43−55 − − − −
0 13 MM 
<1 PCI
21 MM
<1 PCI
54−65 − 23−26 MM 
11−13 PCI
45 6−10 − 43−48 − −
0 − − 100 − 9c
Taiwan 0 − ~8 98 − −
52 2 − 84 − −
Thailand 41 13 − 39−49 − −
34 15 − 24−60 − −
GRACE 30 8 − 18−40 − −
− 5 − − − −
USA 38 2 − 71−87 ‡ − −
40 5 − 80 − −
21 2 (PCI) − 100 − −
Australia/
New 
Zealand
~35 2−4 5−6 − −
21 − 4 − 10
42 − <1a − 2a
China 16 1 − − −
0 1 − − −
Japan ns 7 − − −
Korea 0 − − 15
Malaysia 52* 1 − − −
100 − 12a − 8−13 a
Taiwan ns (53−66 
NSTE-ACS)
2−19 − 7−24 −
GRACE 30 2−8 − 2−8 −
1A: Abbreviations: CPACS = Clinical Pathways for Acute Coronary Syndromes in China;
GRACE = Global Registry of Acute Coronary Events; IH= in hospital; MACE=major ad-
verse cardiovascular event; MM=medical management; PCI = percutaneous coronary
intervention; STEMI = ST-elevation myocardial infarction.
a1-month; b3-month; c6-month; d24-month; e36-month.
*4398patients included2033 (46%)with unlikely ischaemic chest pain, or other diagnosis;
STEMI patients included STEMI and left bundle branch block.
†Patients underwent invasive therapy. Reported in secondary CPACS publication [117].
‡Percent from STEMI cohort.
Rows highlighted green relate to Advisor/other registry data.
For full data set see Supplementary Table 1.
1B: Abbreviations: GRACE = Global Registry of Acute Coronary Events; IH = in hospital;
ns, not speciﬁed; NSTE-ACS = non-ST-segment elevation ACS; STEMI = ST-segment ele-
vation myocardial infarctiona1-month.
*Figures based only on 44% of all cases who had a history of ACS.
Rows highlighted green relate to Advisor/other registry data; DESIRE (July 2001-June
2004); SUNDAY (Jan 2000-Jan 2002).
For full data set see Supplementary Table 1.suggest that ACS-related mortality rates have remained relatively
high at ~5% during hospitalization and up to double this at 1-year
post-discharge (Table 1, and Supplementary Table 1), with the ex-
ception of Australia and New Zealand.
In evaluating trends in management practice, ‘real-world’ registry-
based outcomes data are intuitively representative of the spectrum
of patients encountered in actual clinical practice and a focus on such
data will help in driving future healthcare policy and establishing
region-speciﬁc guideline recommendations. Available registry-based
data showstrong regional heterogeneity in theuse of invasive andphar-
macologic practice patterns, and in short- and long-term clinical out-
comes across the Asia-Paciﬁc region [19,20]; a situation compounded
by the ethnic diversity both within and between Asia-Paciﬁc countries
[19,21].
Existing data strongly suggest that there is much potential for im-
provement in the management of ACS in the Asia-Paciﬁc region. We
assembled leading academic teams from seven countries across this re-
gion in the Asia-Paciﬁc Real world evIdenCe onOutcome and Treatment
of ACS (APRICOT) project, to consider possible approaches towards
improving clinical outcomes in this region based on their experience
and available data towards developing a broad and comprehensive
insight into the issues contributing to ACS-related mortality across
863M.Y. Chan et al. / International Journal of Cardiology 202 (2016) 861–869the Asia-Paciﬁc region. This review provides a summary of the ensuing
discussions.
2. Supporting data
2.1. Search strategy
A systematic PubMed search was conducted (29 May 2013) to
identify ‘real-world’ ACS management data published in the last
20 years from the Asia-Paciﬁc region. From 887 references identi-
ﬁed, those considered by the discussants to provide a sufﬁciently
broad overview of ACS management and mortality across the Asia-
Paciﬁc region (n = 54) were prioritized and used as a ‘reference’
dataset simply to support discussion (details in Supplementary
materials). While potentially subjective, any additional studies/
references or unpublished registry-based data available from the
author's own center or region considered by the authors as appro-
priate to consider were included also.
3.Where are we now? Evidence-based insights to ACS outcomes and
treatment status in the Asia-Paciﬁc region
Based on personal experience and supportive data, the authors
discussed the current status of ACS management in the Asia-Paciﬁc re-
gion; identifying key factors and actions that will potentially impact on,
or improve, outcomes in this region.
3.1. Mortality
Registry-basedmortality data across APAC countries was considered
in terms of disease status and invasive versus non-invasive intervention
(Table 1 and Supplementary Table 1) [21–55].
According to the multinational Global Registry of Acute Coronary
Events (GRACE), which studied 43,810 patients from 1999–2005 in 14
countries excluding Africa and Asia [22] large differences exist in man-
agement practice both by hospital type and geographic location despite
comparable use of antiplatelets and anticoagulants [22]. While mortali-
ty rates at 6months post-discharge, for example, were comparablewith
in-hospital rates (~5%), optimal revascularization and statin use could
prevent up to 32% and 10% of deaths by 6 months, respectively [23].
Greatest survival at 6 months was associated with timely CABG (odds
ratio [OR] for death 0.60; 95% conﬁdence interval [CI] 0.39–0.90) and
PCI (OR 0.57; CI 0.48–0.72), and use of clopidogrel (OR 0.84; CI
0.72–0.99) and statins (OR 0.85; CI 0.73–0.99) [56,57].
In terms of national economic status, the Organization to Assess Strat-
egies for Ischemic Syndromes (OASIS)-1 (low- andmiddle-income coun-
tries, 1995–1996) and OASIS-2 (middle- and high-income countries,
1999–2000) registries – both 2-year prospective studies of outcomes in
NSTE-ACS patients [19] – show little difference in 2-year mortality, de-
spite wide variability in management practices. With the exception of
China, where 2-year mortality was only 7% (attributed to an inherent
low risk of patients in OASIS-2), overall event rates in OASIS-2 remained
high (up to 15%), demonstrating continued risk for long-term mortality,
subsequent MI, refractory angina, and stroke, and the need for new ap-
proaches to reduce risk [19].
Large registries in the Asia-Paciﬁc region such as the Melbourne In-
terventional Group Registry (MIG-R) and the Acute Coronary Syndrome
Prospective Audit (ACACIA) in Australia comprise populations similar to
registries in Europe and Canada [24,25,51,58–60]. Perhaps as expected,
ACACIA, which included propensity adjusted scoring for early invasive
management, showed little difference both in in-hospital and 12-
month ACS-relatedmortality (2–5%) [26] comparedwith other large in-
ternational registries [61–63].
In China, registry-based studies reporting guideline-recommendations
show treatments are implemented in only one-third of STEMI patients,
with many patients not reperfused within recommended times [28] andgenerally high mortality [29,31,32]. Here, the authors expressed
caution given clear heterogeneity in the thoroughness of patient
follow-up, highly variable methods of data collection and treatment
preferences across China (e.g. preferred thrombolysis use in small
hospitals versus PCI in grade 3 hospitals providing specialist health
services), and broad geographical variation in patient risk proﬁles i.e.,
East versus West. Nevertheless, trends towards decreased mortality
rates do relate to improved practice in the emergency room/coronary
care unit, including increased use of coronary angiography (CS Ma,
personal communication).
Data from the treatment and outcomes of acute coronary syndromes
in India (CREATE) registry [33] and the more recent Kerala [34] registry
show that primary PCI rate is much lower in India compared with more
developed countries andwhilemortality rates are generally comparable
they are signiﬁcantly higher in ‘poor’ (8.2%) versus ‘wealthy’ patients
(5.5%) [33,34].
In PCI-oriented countries e.g., Japan andKorea, in-hospital and longer-
term (6–12 months) mortality rates of 7% and 11%, respectively, were
generally higher than for the non-Asian GRACE population (5–6%) [22,
23,52,64–67]. Recent reports of low mortality rates in-hospital (2%), and
at 12 (4%) and 24 (6%)months from the Prevention of AtherothrombotiC
Incidents Following Ischemic Coronary Attack (PACIFIC) registry, [38], can
be attributed to proactive performance of PCI. ACS-related outcomes in
Korea, are generally comparable with Japan [39], although the
Korea Acute Myocardial Infarction Registry (KAMIR) data did show rela-
tively high rates for invasive intervention versus other registry reports
and greater mortality for NSTEMI patients long-term (11 month)
compared with in-hospital and 1-month mortality [39,68]. These
observations suggest a need for more patient-centric intensive sur-
veillance and treatment while the KAMIR cohort data per se may
present unique characteristics in Korean PCI practice as well as con-
temporary trends in PCI.
Based on the Malaysian National Cardiovascular Disease (NCVD)-ACS
registry (Malay 49%, Chinese 23%, Indian 23%), ﬁbrinolysis use was rela-
tively high (N70%) and use of invasive procedures low (13–17%) versus
other registries. Reported in-hospital and 1monthmortalitywas reported
as higher in Malay patients (7%) compared with other ethnic groups
(4–6%) and rates fromother Asian registries [41,42,54,69,70] and attribut-
ed to ahigh prevalence of risk factors and complex andhigh-risk coronary
lesions in theMalay cohort alongwith relatively lowuse of invasiveman-
agement and timely reperfusion.
Singapore is one of few countries in the Asia-Paciﬁc region with a
state-funded national MI registry i.e., the Singapore Myocardial Infarct
Registry (SMIR) Patients hospitalized for AMI from 2000–2005 showed
in-hospital mortality (6–10%) to be generally comparablewith the non-
AsianGRACE cohort (7%) [46] but higher than the cohort from the study
of ACS care across Australia and New Zealand (SNAPSHOT ACS: 4.5%)
[26]. It was noted, however, that the Singapore population comprises
primarily third and fourth generation migrants of Han Chinese, Indian
(South Asian), and Malay (Austronesian) descent.
In Taiwan, a 12-monthmortality rate of ~8% in patientswith ACS ad-
mitted to the hospital within 24 h of symptom onset andwhere 97% re-
ceived primary PCI, was perhaps higher than expected [47,48,71].
Notably, there is, a signiﬁcant lag/deviation from evidence-based guide-
lines in ACS management in Taiwan, notably, use of DAPT, which fell
from 75% at discharge to 25% at 1-year follow-up, and other secondary
preventive therapies [47,71] suggest more stringent policy adherence
may improve long-term outcomes in ACS patients.
Similarly high ACS-related mortality is evident in Thailand (~10–15%
in-hospital, and up to 25% at 12 months follow up) although generally
conﬁned to elderly patients and those who received only conservative
(non-invasive) treatment without coronary angiogram [49,50,72,73]. A
more recent evaluation of registry data did show a signiﬁcant decrease
in in-hospital mortality (~6%), with 12-month mortality for NSTEMI
[25%] remaining virtually double that for STEMI [74]; however, differ-
ences in characteristics and severity of the enrolled patients confound
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should be considered further.
3.2. Practice patterns and access to resources
Data from the MIG-R indicate signiﬁcant changes in interventional
management between 2004–2005 and 2007–2008, with fewer elective
but more urgent PCIs, and increased long-term use of clopidogrel for
DES [75]. Consequently, the generally lower ACS-related mortality
seen in Australia compared with the US [61–63], for example, was at-
tributed in part, to greater uniformity of treatment in teaching hospitals
and more timely access to reperfusion including triage from ambulance
to catheterization department (D Eccleston, personal communication).
Additionally, transition of care is considered increasingly critical to im-
prove outcomes and many major cities in Australia now have centers
with 24/7 primary PCI facilities with paramedics ‘upskilled’ to perform
ambulance-based triage (i.e., in-ambulance ECG and direct transfer to
catheterization laboratory for PCI).
Beneﬁts from optimal acute and pre-/post-discharge treatment are
supported by other registry-based studies, such as the SNAPSHOT ACS
study, and theGenesis Heart Care GroupRegistry (GHCGR),which dem-
onstrate variability in resources and in-hospital MACE rates across dif-
ferent healthcare jurisdictions [26,76].
Prospective observational studies conﬁrm close compliance with
guideline-based recommendations for medical management in China,
although mortality in in-hospital and by 12 months post discharge
remains high, particularly in STEMI patients (Table 1) and in women
who are generally older than men, associated mainly with poor access
to treatment and manifest delayed time to reperfusion [27–29,31,32,77,
78]. Beneﬁt of improved access to treatment is supported by
twosingle-center registry studies inACSpatients (DESIREandSUNDAY)–
albeit mainly in relatively low-risk UA patients receiving PCI (61%) or
CABG (94%), DAPT (60%) and antiplatelet monotherapy (30%) – where
a median symptom-to-balloon time of only 8.1 h was associated with
in-hospitalmortality of 1%, which increased to only 4% at 2 years (DESIRE
and SUNDAY; author unpublished data) (Table 1).
Beneﬁts from optimal acute and pre-/post-discharge treatment are
also supported by the Kerala registry, and theDetection andManagement
of Coronary Heart Disease (DEMAT) registry in India [20]. Although use of
standard pharmacotherapies generally mirrors guidelines and Western
registries [34], optimal in-hospital and post-discharge treatment rates
are relatively low [20]. The observation that provision of optimal in-
hospital medical care was associated with a 21% lower risk of in-
hospital MACE and provision of optimal discharge medical care led to
the suggestion that strategies to improve overall ACS care in India should
initially focus on an improved in-hospital process-of-care. Indeed, in
Japanwhere PCI is frequently used and ~94% of ACS patients aremanaged
in centers with 24/7 primary PCI facilities, registry- and observational
study-based data show that a shorter time from symptom onset to inter-
vention is associated with better long-term clinical outcomes and, specif-
ically, an onset-to-balloon time of ≤3 h provides better 3-year clinical
outcomes [36,38,79].
Similarly, in Korea most ACS patients undergo PCI (~90% receiving
DES) [39,40,53,68,80–82]. Here, triple anti-platelet therapy including
adjunctive cilostazol is frequently used in high-risk PCI patients as it is
more effective than standard DAPT in reducing cardiovascular and
total mortality, both in-hospital and at 8months. Although an increased
pharmacotherapy index (up to nine concomitant therapies) provides a
trend towards lower in-hospital mortality irrespective of disease status,
the prescribing of evidence-based therapy in Korea is generally sub-
optimal with a need for new educational strategies to increase the
use of secondary prevention measures [53,81].
According to the Malaysian NCVD-ACS registry, approximately half
of patients with ACS undergo primary PCI generally with adoption of
good practice for DAPT. Notably, such patients tend to be relatively
young with a high prevalence of risk factors (e.g., diabetes), complexhigh-risk lesions and a median door-to-balloon time for primary PCI
(98 min) higher than recommended (b90 min), nevertheless, high
procedural success and good pharmacotherapy is associated with a low
in-hospital mortality rate (1%) comparable with other registries [42].
In Thailand, which employs a non-PCI and a non-reimbursement
policy, ACS-related mortality is generally high. Despite this, improve-
ment inmortality was evident from the Thai Registry in Acute Coronary
Syndrome (TRACS, 2007–2008) registry and attributed to a generally
better disease status, more PCIs performed, and improved door-to-
needle time [49,74]. Nevertheless, ACS-related mortality remains rela-
tively high, and reduced times between ﬁrst medical contact and treat-
ment, and optimal use of pharmacotherapy post-discharge will perhaps
be key to improving outcomes.
3.3. Ethnic differences
Ethnicity is an important factor in regard to outcomes. For example,
5-year follow-up of a contemporary cohort of Singapore Indian, Chinese
and Malay patients showed clear ethnic disparities in long-term out-
comes despite minimal disparities in in-hospital management with
Singapore Indians having the lowest long-termmortality [83]. Although
the reason is unclear, Singapore Indians generally belong to the highest
socio-economic class, exercise most frequently, smoke the least and ad-
here most often to healthy food choices [84] suggesting that differential
outcomes in different ethnic groups may be due to inter-ethnic socio-
cultural and socioeconomic differences along with inherent (genetic)
risk factors (e.g. diabetes in India). Further studies are needed to gain
understanding of potential variability in compliance and racial differ-
ences in rates of disease progression or response to drug therapy.
3.4. Gender differences
US-based registry studies conﬁrm that women with ACS are gen-
erally older and present more comorbidities than men [63], notably,
between-gender differences in demographic, clinical, and treatment
proﬁles are associated with greater risk of bleeding in female patients
with MI undergoing PCI [85]. Similarly, in China, greater acute and post-
discharge (1-year)mortality inwomen comparedwithmenwas associat-
ed with older age and less frequent receipt of reperfusion therapy [32]. In
Korea, higher in-hospital and 1-year mortality in women was associated
with a higher frequency of comorbidities, longer pain-to-door time, and
more severe hemodynamic status [40,82,86]. In contrast, in India
and Singapore, in-hospital management, discharge management, and
outcomes generally did not differ between genders [20], although, in
Singapore youngerwomenwithdiabeteswere considered to be at greater
risk (adjusted hazard ratio [HR] vs N60 years, 1.35; 95% CI, 1.04–1.75) (F
Gao, personal communication).
Collectively, these observations support an association between
healthcare system quality, gender inequality, and ACS management
and outcomes; women tend to be undertreated and, as both genders
beneﬁt from revascularization, a more aggressive approach is needed
in women, including optimization of discharge medical regimens and
improved compliance.
3.5. Education
Lack of patient education towards, chest pain awareness, the need
for good treatment compliance, and the relative importance of medica-
tion types e.g., in multi-pill prescribing, alongside poor and/or delayed
access to facilities, represents considerable barriers to improving out-
comes. Speciﬁcally, poor patient education results in poor adherence/
compliance with treatment associated with, for example, poor knowl-
edge as to which dose/type of medication missed would present more
signiﬁcant consequences e.g., antiplatelet versus statin.
The implementation of post-hospital coaching programmes e.g., the
Coaching patients On Achieving Cardiovascular Health (COACH)
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outcomes, both short-term (12 months) and longer-term (4-year
follow-up) [87,88]; ‘aware’ patients are eight times more likely to be
compliant than their counterparts as to the cardiac risks associated
with non-compliance [89]. Along with the possibility the prevalence
of non-compliance is likely underestimated due to recall bias and self
under-reporting [89], improved patient education through sustained
educational initiatives remains a key target for improving outcomes.
3.6. Pharmacotherapy support
In Australia, clopidogrel administered in-hospital is reimbursed and
largely subsidized post-discharge but a gap still exists in pharmacother-
apy use for secondary prevention [90–92]. Moreover, while DAPT typ-
iﬁes standard of care in Australia, adherence up to 12 months is only
60–70% [92,93] suggesting improvement in controlling risk factors,
while increasing access and adherence to new pharmacologic therapies
e.g., single-tablet CoPlavix,might improve compliance and outcomes. In
contrast, ACS-related prescription adherence at 12 months post dis-
charge in Singapore remains relatively high i.e., ≥96% including for aspi-
rin and P2Y12 antagonists but improvement is needed, in monitoring of
prescription adherence and patient adherence during transition from
tertiary to primary care.
In China and India there is high reliance on thrombolysis reperfusion
(53%) versus PCI (12%) and CABG (0.1%) and most patients receive
DAPT for at least 1 year following such procedures (Supplementary
Table 2) [31,33,34]; there have, however, been no recent approvals for
newer antiplatelet agents. Recent evidence showing that short-term
DAPT (3–12 months) provides favourable clinical outcomes versus
long-term use (12–24 months) [94–97] and that prolonged DAPT may
beneﬁt high-risk patients (AMI, diabetic, ESRD), and those receiving in-
tervention for management of complex lesions [98], suggests a need for
patient management individualized according to patient risk factors,
disease activity and severity.
Accumulatingdata support variable hypercoagulability and associat-
ed clinical risk, and pharmacokinetic, pharmacodynamic, and pharma-
cogenetic proﬁles of cardiovascular drugs across ethnic cohorts [99].
ComparedwithWestern cohorts, East Asian populations (including Chi-
nese, Japanese, and Korean) demonstrate unique clinical outcomes as-
sociated with antithrombotic therapy, including increased levels of
platelet reactivity (clopidogrel) and risk of bleeding events [100–107],
or increased exposure to active metabolite (prasugrel and ticagrelor)
[108–110]. In fact, this so-called “East Asian Paradox” has resulted in a
different target international normalized ratio (1.6 to 2.6) being imple-
mented in clinical practice among East Asian patients [111,112].
Recent randomized clinical trials of prasugrel and ticagrelor in East
Asian patients support earlier large-scale studies in demonstrating
that potent P2Y12 receptor inhibitors can provide clinical beneﬁt over
clopidogrel in reducing risk from serious bleeding [113–116]. The mod-
est sample sizes of Asian-speciﬁc trials does, however, limit their ability
to deliver reliable conclusions, although signals of ethnic differences in
the efﬁcacy-safety balance of conventional antithrombotic drugs in
East Asian patients e.g., increased tendency for bleeding for ticagrelor,
may pose concern and further support tailoredmanagement. Neverthe-
less, such trials may help identify effective combinations of new potent
antiplatelet therapieswith older agents e.g., aspirin and clopidogrel, and
which potentially circumvent resistance and/or non-response to these
agents. However, long-term real-world data from the Asia-Paciﬁc re-
gion are needed to fully assess the beneﬁt to risk proﬁle for new anti-
platelet therapies.
3.7. Cost and adherence to treatment
Treatment cost to the patient is also a major barrier to long-term
medication use in most countries in the Asia-Paciﬁc region, a situation
shown recently to be associated with poor patient awareness of theconsequences of non-compliance [89]. In China, fewer than 40% of pa-
tients remain adherent to medication at 12 months post-discharge,
mostly due to patient refusal [117] Signiﬁcantly, however, patient
non-adherence to antiplatelet agents is frequently due to their doctor
considering them not indicated for such treatment, a situation
compounded by different reimbursement mechanisms in cities versus
rural areas. Cost issues also apply in India where 75% of patients pay for
their own treatment. Notably, poorer patients have signiﬁcantly higher
mortality versus richer patients, a trend associatedwith lower rates of ap-
propriate treatments and delays to intervention and door-to-balloon or
-needle times frequently outside of recommended limits [33]. While de-
lays to treatment are often economic in origin, reliance on private or pub-
lic transport often further delays access to secondary- or tertiary-care
hospitals [33].
In Taiwan, most patients are covered by healthcare insurance but
with evident lag/deviation from evidence-based guidelines in ACSman-
agement [47,71]. Although adherence to DAPT for ≥9 months is associ-
ated with signiﬁcantly lowermortality at 12months versus antiplatelet
monotherapy, the prescription rate of post-PCI DAPT shows a decline
following discharge to 12 months (62–13%) with physicians citing the
Bureau of National Health Insurance guidelines as the reason for
discontinuing [clopidogrel] in 25% of cases [47]. Additionally, reim-
bursement appears variable and dependent upon the treatment re-
ceived and affordability, for example, clopidogrel is covered for only
3 months following BMS implantation, compared with 9 months for
other treatment modalities. Thus, overall, patient/physician education,
adherence both to treatment and guidelines, and appropriate cost to
the patient are crucial factors towards improving outcomes across the
Asia-Paciﬁc region.
4. Discussion
Based on current practice patterns, the authors considered where
we are now and what the barriers are to further improve outcomes in
the Asia-Paciﬁc region.
4.1. Barriers to improving ACS outcomes in the Asia-Paciﬁc region
Several key areaswere discussed, a consistent observation across the
Asia-Paciﬁc region being the strong emphasis on ‘benchmark’ short-
term clinical outcomes (e.g. in-hospital events and those occurring
within 6 months of the index event) and relatively weak emphasis on
long-term outcomes associated with inherent challenges posed by
long-term follow-up per se and maintaining compliance.
Geography is the key barrier to timely in-hospital and post-
discharge management in Australia and New Zealand. To support
transition of care e.g., from remote areas, Australian health authori-
ties are trialling pre-hospital/in-transit antithrombotic intervention
supported by communication with the main cardiology treatment
center. Evidence suggests that this approach, along with a clear in-
hospital rapid triage pathway, markedly reduces door-to-balloon
times. However, the potential real world utility of such intervention
remains to be conﬁrmed. In China, Hong Kong, India, and Taiwan,
the provision of patient/public education towards chest pain aware-
ness, need for compliance, and effective primary (e.g., lifestyle
changes) and secondary prevention requires further considerable
resource e.g., trained nurses and improved medical/health system
procedures. These are not sufﬁciently robust at present, which con-
tributes markedly to protracted total ischemic time i.e., prolonged
symptom-to-treatment times in Taiwan and India. Effective assess-
ment of patient understanding may help optimize compliance.
From a study of adherence to antiplatelets post-coronary stenting,
greatest awareness and compliance was seen among patients pro-
vided with information through the media and health talks, rather
than a cardiologist [89]. Similarly, physician education may help
through improved information transfer to patients. In China, many
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physician considers them ‘not indicated’. Adoption of guideline-
recommended pharmacotherapy is poor over both the short- and
medium-term and appears to be determined by factors other than
risk of a recurrent event [117]. In India, there is a need to implement
robust protocols for in-hospital treatment, reperfusion procedures,
allocation of discharge medications, and the appropriate use of
thrombolysis.
Continuity of care, i.e., transition from tertiary to primary care, is a
major barrier to improved outcomes in Japan and Singapore, as is sec-
ondary prevention in Hong Kong. Improved patient and doctor aware-
ness and improved outcomes might accrue through national medical
education programmes (not yet implemented in Japan) and focus on
educating those patients likely to understand the importance of compli-
ance. In Singapore, improving continuity of care represents a policy-
based resource allocation problem, currently better for the tertiary ver-
sus primary care sector.
4.2. Strategies to improve ACS outcomes in the Asia-Paciﬁc region
The APRICOT working groupmade several key strategic recommen-
dations to improve ACS outcomes in the Asia-Paciﬁc region: longer-
term patient surveillance, greater patient education (pain awareness,
compliance, primary/secondary prevention), overcoming geographical
challenges to pre-hospital and post-discharge care, and the adoption
of value-based over cost-based healthcare systems. The group recom-
mended a greater emphasis on improving longer-term outcomes in
ACS. Also, an opportunity exists to improve follow-up andmonitor com-
pliance, particularly where patient history is already on record;
programmes such as the ongoing NCDR-GWTG programme in the USA
[118] have conﬁrmed that recording of treatment received and out-
comes achieved improved quality of care [119]. Poor patient compliance
and adherence may be improved through community outreach to re-
cord adherence at 12 months, possibly via mail, telephone question-
naire, or during a hospital visit. Selected high-risk/low-compliance
patients may then be entered into a compliance pathway to allow focus
of resources towards patients most at risk. Technology-based solutions
such as telemedicine may also aid community outreach programmes by
circumventing the need to commute long distances between remote re-
gions and healthcare facilities.
Greater patient education is needed to improve awareness of ACS-
related chest pain to reduce time-to-treatment, and understanding of
the need for adherence. Likewise, the US NCDR initiative has shown
that performance measurement and feedback to hospitals and
healthcare providers is effective in improving adherence to guide-
lines and could form a basis for medical reform and development
of quality-of-care indicators. Against this scenario, patient engage-
ment might be improved through implementation of broad commu-
nity outcomes, including online consultation programs in large
community hospitals.
Although large-scale randomized clinical trials such as TRITON-TIMI
38 [115] and PLATO [116] show an overall beneﬁt of potent P2Y12 inhib-
itors versus clopidogrel in ACS, these studies enrolled only less than 6%
of patients from the Asia-Paciﬁc region. Signiﬁcantly, many cardiovas-
cular drugs show differing pharmacokinetic, pharmacodynamic, and
pharmacogenetic proﬁles across ethnic cohorts. For example, East
Asian patients (including China, Japan, and Korea) show a lower anti-
platelet effect to clopidogrel compared with Western patients, due to
genetic polymorphisms that confer resistance to this drug [120–123];
recent clinical studies have shown East Asians may have an inherently
different therapeutic zone of platelet reactivity during P2Y12 inhibitor
treatment and require different dosing regimens compared with West-
ern populations [99]. The recent PRASFIT-ACS study supported this con-
cept, showing that low-dose prasugrel therapy (20 mg loading and
3.75 mg daily) reduced the risk of composite ischemic events by 23%
compared with standard-dose clopidogrel therapy (300 mg loadingand 75 mg daily) [113]. Dedicated pharmacodynamic studies and clini-
cal trials are urgently required to elucidate speciﬁc guidelines for anti-
platelet agents among East Asians, in particular, antiplatelet effects
with prasugrel and ticagrelor. We also need to strongly consider the
paradigm shift from ‘one-guideline-ﬁts-all races’ to ‘tailored antiplatelet
therapy’ for different ethnic cohorts.
Asian subjects derive similar beneﬁts as Western subjects at lower
statin doses [124]. Unfortunately, the pharmaceutical industry often
considers it ﬁnancially non-viable to fund a large Asian-speciﬁc late-
phase trial after a successful pivotal trial. A possible alternative would
be to design and perform registry-based randomized controlled trials,
such as the Thrombus Aspiration in ST-Elevation myocardial infarction
in Scandinavia (TASTE) trial [125], that leverage existing ACS registries
in Asia-Paciﬁc countries.
Background medications other than DAPT are equally important in
lowering residual risk and improving outcomes after an ACS. While ge-
neric formulations are now widely available for many proven back-
ground medications for ACS, including ACE-I/ARB, β-blockers, and
statins, their long-term use for several decades after an ACS event will
entail signiﬁcant costs to healthcare systems. The APRICOT group rec-
ommends seeking more sustainable models of prescription ﬁnancing,
including private-public partnerships of cost sharing and a ‘right pa-
tient, right drug’ approach. Such amodel is presently practised in select-
ed public hospitals in Singapore, in which universal access to high-cost
but high-efﬁcacymedication like ticagrelor is restricted to patients with
troponin-positive ACS. As the efﬁcacy-safety balance is maximised in
troponin-positive ACS [126], healthcare management systems may be
more willing to pay for a high-efﬁcacy but high-cost drug for a limited
12-month period. Such a ‘right patient, right drug’ approach is already
widely applied to high-efﬁcacy high-cost drugs such as herceptin for
oestrogen receptor-positive breast cancer. Further incentives for both
public and private partners could be a reduced drug cost if patients ad-
here to the full 12-month prescription and the exclusive use of generic
formulations manufactured by the original company after patents end.
It was generally acknowledged that multi-pill prescribing can ad-
versely impact upon compliance in many countries disadvantaged by
geographic distance, while randomized controlled trials of the poly-
pill formulation have shown signiﬁcantly improved medication adher-
ence in patients at high CVD risk [127] and potential utility in the
acute ACS setting [34]. Strategies to improve in-hospital and discharge
medical therapies, perhaps including the poly-pill formulation in the
acute phase along with timely reperfusion, are important towards im-
proving local process-of-care measures and ACS outcomes in remote
geographic regions [20].
5. Conclusions
ACS remains a leading cause of mortality and morbidity in the Asia-
Paciﬁc region.While much effort has beenmade over the last decade to
improve diseasemanagement, high variability inmanagement practices
and outcomes between countries and regions is still prevalent. This
manuscript provides comprehensive insight for seven countries across
the Asia-Paciﬁc region into the problems currently being experienced
in managing ACS across this region.
ACS-relatedmortality rates in this region remain high – around5% in
in hospital and up to double this post-discharge – and there ismuch po-
tential for improvement. Inherent risk factors are key determinants of
outcomes in different ethnic groups, for example, a situation com-
pounded by regional differences in AMI incidence in metropolitan versus
rural districts. Improving outcomes will be multifactorial. Key ‘bar-
riers’ towards improving outcomes in this region include patient educa-
tion, the impact of geographical landscape, limited long-term adherence
to guideline-based management, and the widespread adoption of cost-
based rather than value-based healthcare systems.
Initiatives to overcome these barriers should include the implemen-
tation of pre-hospital management strategies, toolkits to aid in-hospital
867M.Y. Chan et al. / International Journal of Cardiology 202 (2016) 861–869treatment, greater community outreach with online patient/physician
education and telemedicine, sustainable economic models to improve
accessibility to effective pharmacotherapies, and secondary prevention
initiatives distilled from high-quality ‘real-world’ data.
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